Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Clinic Secret is a telehealth platform providing licensed access to GLP-1 weight loss treatments like Ozempic, semaglutide ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...

Novo Nordisk (NYSE: NVO) and Intuitive Surgical (NASDAQ: ISRG) are both healthcare leaders, but they operate in different ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

In topline results of the ATTAIN-MAINTAIN trial, people who lost weight with an injectable GLP-1 were able to keep weight off when switched to an oral GLP-1, Eli Lilly announced.For ATTAIN-MAINTAIN, ...

Novo Nordisk (NVO) stock gains as the company files for FDA approval of CagriSema, its next-gen obesity drug which causes up ...

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.